Amyotrophic Lateral Sclerosis (ALS)

World-first MND drug trial offers hope to those living with the disorder

FDA OKs Phase 1/2 clinical trial of small molecule SPG302 in ALS

FDA clears investigational new drug application for clinical trial of ALS pill

Synapse-Generating Small Molecule for ALS Receives Nod from FDA for Clinical Trial

FDA grants IND clearance for Spinogenix’s ALS treatment trial

Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

Spinogenix’s Daily Pill SPG302 Receives FDA IND Nod for ALS Treatment

A Promising Treatment for MND

A new drug that could reverse the worst symptoms of MND is about to be trialled in Australia.

Novel motor neurone disease, MND, drug SPG302 to be trialled in Australia

HERALD SUN AUSTRALIA, By Sarah Booth Australian motor neurone disease patients will be the first in the world to trial a “novel” treatment that scientists hope could not only slow — but actually reverse — the condition. If successful, the US biotech firm Spinogenix drug would be the first regenerative treatment for the devastating and…